Search

Displaying results 3801 - 3810 of 8010 in total
  1. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    [A187907] Crizanlizumab, or SEG101, is given once every 4 weeks and may improve patient adherence. It was developed by Novartis and was granted FDA approval on November 15, 2019. … Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels.

  2. Drug

    Azaperone

    go.drugbank.com/drugs/DB11376
    InvestigationalVet approved

    At the same time, the agent generally does not see equine use as particular adverse reactions may happen. More rarely it may be used in humans as an antipsychotic drug, but this is uncommon. … It is subsequently employed predominantly as a veterinary tranquilizer and mainly for pigs and elephants.

  3. Drug

    Carbon dioxide

    go.drugbank.com/drugs/DB09157
    ApprovedInvestigationalVet approved

    during bodily investigations, to inflate body cavities during surgery (such as key-hole surgery), and in solid form (dry ice) for freezing of tissue and removal of warts.

  4. Drug

    Norelgestromin

    go.drugbank.com/drugs/DB06713
    ApprovedInvestigational

    [L63816] Combined hormonal contraceptives containing norelgestromin lower the risk of pregnancy primarily by suppressing ovulation.

    Categories: Hormonal Contraceptives for Systemic Use
  5. Drug

    Picrotoxin

    go.drugbank.com/drugs/DB00466
    Experimental

    Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. [PubChem]

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Semzuvolimab

    go.drugbank.com/drugs/DB18920
    Investigational

    Semzuvolimab is under investigation in clinical trial NCT03149211 (To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults).

  7. Drug

    CYNK-101

    go.drugbank.com/drugs/DB18637
    Investigational

    CYNK-101 is an allogeneic human placental hematopoietic stem cell-derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP).

    Synonyms: allogeneic human placental hematopoietic stem cell derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP)
  8. Drug

    Sodium iodide

    go.drugbank.com/drugs/DB11119
    ApprovedInvestigational

    Sodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition [L2065] but is more commonly used in veterinary medicine.

    Mixtures: FERTOMCIDINA U, FERTOMCIDINA U
  9. Drug

    Perflubron

    go.drugbank.com/drugs/DB05791
    Investigational

    Perflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808,L63933] Zidesamtinib is selective for ROS1, retains activity in cells carrying the common resistance mutations, and showed antitumor activity in an intracranial model, positioning it for use after … [L63808] The FDA approved zidesamtinib on July 22, 2026, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received a prior ROS1 kinase inhibitor.